AbbVie Q3 Revenue of $17.4B Beats Expectations, Raises Full-Year EPS Guidance and Hikes Dividend by 5.2%
nashnova research
AbbVie posted Q3 revenue of $17.4 billion and adjusted EPS of $3.82, both above Wall Street estimates; the company raised full-year profit guidance and hiked its dividend by 5.2%, signaling confidence in its post-Humira growth trajectory.
How much did this quarter actually beat by?
Q3 revenue came in at $17.4 billion, up 10% year-over-year, topping the FactSet consensus of $17.32 billion.
Adjusted EPS of $3.82 beat the Street's $3.73 estimate by roughly 2.4%.
This means → the beat isn't massive, but revenue and earnings both clearing the bar together points to solid, broad-based growth rather than one line item doing the heavy lifting.
Humira is still sliding — what's filling the gap?
Humira — once the world's best-selling drug — brought in just $683 million, down 31.2% year-over-year as biosimilars (lower-cost copies of biologic drugs) keep taking share.
Yet the immunology segment overall posted $9.17 billion, up 16.3%, confirming the old-to-new handoff is complete.
The two successors: Skyrizi delivered $5.78 billion and Rinvoq $2.71 billion in the quarter — together accounting for nearly half of total company revenue.
In plain terms = Humira is fading fast, but its replacements are growing far faster than the legacy drug is shrinking. This is the "transition complete" signal the market has been waiting for.
Why did net income surge year-over-year?
Q3 net income was $4.22 billion ($2.37 per share), versus just $186 million ($0.10 per share) a year ago — more than a twentyfold increase on paper.
This means → the jump is mostly a base-effect story, not a sudden business explosion. Last year's quarter was weighed down by $1.50 per share in acquired-IPR&D and milestone charges; this year that drag shrank to just $0.11.
In plain terms = last year's profits were crushed by a one-time bill from acquisitions. That bill is now largely paid off, so earnings snapped back to normal. Adjusted EPS of $3.82 is the better gauge of real operating performance.
What does the guidance raise signal?
Full-year adjusted EPS guidance was lifted to $13.95–$13.99, up from the prior range of $13.76–$13.96 and above the Street's $13.91 estimate.
The quarterly dividend was raised 5.2% to $1.82 per share — a direct cash-return signal to shareholders.
This reflects management's conviction that the post-Humira growth curve is durable — raising guidance and the dividend simultaneously says the cash-flow outlook is secure.
What does the Apogee acquisition bring?
AbbVie recently closed its acquisition of Apogee Therapeutics, gaining the experimental drug zumilokibart.
The drug targets moderate-to-severe atopic dermatitis — the most common form of eczema — and is positioned as a potential competitor to Regeneron and Sanofi's blockbuster Dupixent.
This means → atopic dermatitis is a multi-billion-dollar market, but Dupixent already dominates it. Whether zumilokibart can mount a real challenge is the key validation milestone to watch going forward.
How are the other business lines doing?
The neuroscience portfolio posted $3.39 billion in revenue, up 19.4% — the fastest-growing segment outside immunology.
Oncology revenue edged up 0.8%, essentially flat.
Aesthetics revenue dipped 1.4%, under modest pressure.
In plain terms = neuroscience is the clear second growth engine. Oncology and aesthetics aren't dragging the company down, but they're not contributing meaningful growth either.
市场有风险，内容仅供研究参考，不构成投资建议。